Switzerland-based Roche has launched cobas 6500, a fully automated urine testing system that consists of two modular analysers combining urine strip testing and digital urinary microscopy.
Cobas 6500 tests for 23 parameters to help diagnose diseases such as urinary tract infection, kidney disease and diabetes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The urine test strip analysis module quickly tests for the risk of diseases such as kidney disease and urinary tract infection.
The second module replaces the manual steps included in urine microscopy and provides fully automated quantification and classification of urine particles such as blood cells by digital microscopy.
The system offers the highest throughput on the market, ensuring high-quality results and increases laboratory productivity significantly, while reducing manual steps and contamination risks for laboratory staff, according to the company.
Roche Diagnostics COO Roland Diggelmann said: "With the cobas 6500 we can offer fully automated urine testing to laboratories, processing more than 1,000 urine samples per day, which is significantly more than what can be done today.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"Building on our 50 years of experience in urine analysis, Roche Diagnostics is now entering digital microscopy for urine testing, bringing even higher-quality solutions to the laboratories.
"This enables laboratories to generate faster and more reliable results for the benefit of people’s health."
According to the company, cobas 6500 will be available in Europe, the Asia Pacific region, the Middle East, Africa and Latin America.
The company is also planning to file an application for the approval of the cobas 6500 in the US.
